Functional Dyspepsia Treatment Trial

Acronym: FDTT NIDDK Contact: Frank Hamilton Principal Investigator(s): Not Available


The FDTT study is a multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities.

Click outside of the light box to close the box.